Aprea Therapeutics Inc.
| NASDAQ: APRE | Healthcare / Biotechnology / USA |
| 3.64 | -0.0600 | -1.62% | Vol 1.48K | 1Y Perf -61.02% |
| Dec 6th, 2023 13:29 DELAYED |
| BID | 3.64 | ASK | 3.75 | ||
| Open | 3.60 | Previous Close | 3.70 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 3.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | -17.58 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/33/-56 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | 100/-2/-86 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/42/-36 | Income Ranking | — - | |
| Price Range Ratio 52W % | 9.33 | Earnings Rating | — | |
| Market Cap | 13.60M | Earnings Date | 8th Nov 2023 | |
| Alpha | 0.33 | Standard Deviation | 2.90 | |
| Beta | 2.20 |
Today's Price Range 3.603.91 | 52W Range 2.7812.00 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.00% | ||
| 1 Month | -11.44% | ||
| 3 Months | -6.19% | ||
| 6 Months | 2.54% | ||
| 1 Year | -61.02% | ||
| 3 Years | -99.41% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -72.38 | |||
ROE last 12 Months | -294.79 | |||
ROA (5Y Avg) | -36.31 | |||
ROA last 12 Months | -245.51 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -293.45 | |||
Return on invested Capital Q | -2 382.70 | |||
Return on invested Capital Y | -15.01 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.10 | ||||
| 0.91 | ||||
| - | ||||
| - | ||||
| -1.20 | ||||
| -1.24 | ||||
| 0.91 | ||||
| 0.50 | ||||
| -8 850 950.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.30 | ||||
| 8.40 | ||||
| 0.00 | ||||
| 0.00 | ||||
| -7 393.30 | ||||
| Leverage Ratio | 3.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -1.08 | -0.86 | 20.37 |
| Q02 2023 | -1.43 | -0.87 | 39.16 |
| Q01 2023 | -1.51 | -1.34 | 11.26 |
| Q04 2022 | -2.60 | -0.92 | 64.62 |
| Q03 2022 | -5.60 | -2.40 | 57.14 |
| Q02 2022 | -7.60 | -19.80 | -160.53 |
| Q01 2022 | -7.60 | -7.20 | 5.26 |
| Q04 2021 | -8.80 | -7.20 | 18.18 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -1.08 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.48K |
| Shares Outstanding | 3.74K |
| Shares Float | 2.96M |
| Trades Count | 26 |
| Dollar Volume | 5.54K |
| Avg. Volume | 7.99K |
| Avg. Weekly Volume | 9.06K |
| Avg. Monthly Volume | 4.67K |
| Avg. Quarterly Volume | 10.22K |
Aprea Therapeutics Inc. (NASDAQ: APRE) stock closed at 3.64 per share at the end of the most recent trading day (a -1.62% change compared to the prior day closing price) with a volume of 1.48K shares and market capitalization of 13.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Aprea Therapeutics Inc. CEO is Oren Gilad.
The one-year performance of Aprea Therapeutics Inc. stock is -61.02%, while year-to-date (YTD) performance is -45.02%. APRE stock has a five-year performance of %. Its 52-week range is between 2.78 and 12, which gives APRE stock a 52-week price range ratio of 9.33%
Aprea Therapeutics Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -245.51%, a ROC of -293.45% and a ROE of -294.79%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aprea Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. Aprea Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aprea Therapeutics Inc. is Strong Buy (1), with a target price of $3, which is -17.58% compared to the current price. The earnings rating for Aprea Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aprea Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aprea Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.52, ATR14 : 0.26, CCI20 : -83.50, Chaikin Money Flow : -0.08, MACD : -0.12, Money Flow Index : 62.66, ROC : -7.50, RSI : 43.87, STOCH (14,3) : 18.03, STOCH RSI : 0.50, UO : 29.45, Williams %R : -81.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aprea Therapeutics Inc. in the last 12-months were: Seizinger Bernd (Buy at a value of $36 954)
Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
CEO: Oren Gilad
Telephone: +1 617 463-9385
Address: 535 Boylston Street, Boston 02116, MA, US
Number of employees: 16
TipRanks News for APRE
Fri, 06 Oct 2023 17:25 GMT Promising Outlook for Aprea Therapeutics: A Buy Rating Based on Upcoming Safety Data and Synthetic Lethal Targeting Potential
- TipRanks. All rights reserved.Thu, 21 Sep 2023 11:47 GMT Aprea Therapeutics (APRE) Gets a Buy from Maxim Group
- TipRanks. All rights reserved.
